



**Figure S4.** End-of-treatment quit rates in the PNAT2 trial by treatment group and metabolizer group among AFR only: ARF wGRS tested. Odds ratios (OR) with 95% confidence intervals (CI) comparing the efficacy of varenicline versus the nicotine patch. Metabolizer-by-treatment interaction effects on end-of-treatment quit rates evaluated by the ratio of odds ratios (ORR) with 95% CI. (A) NMR stratification (slow:  $NMR < 0.31$ , normal:  $NMR \geq 0.31$ ) in the genetically determined AFR subset of the varenicline and nicotine patch treatment arms ( $N=275$ ). (B) wGRS stratification (slow:  $wGRS < 2.089$ , normal:  $wGRS \geq 2.089$ ) in the genetically determined AFR subset of the varenicline and nicotine patch treatment arms ( $N=275$ ).